Personalized medicine and stroke prevention: where are we?

Joosup Kim1,2
Amanda G Thrift1
Mark R Nelson3
Christopher F Bladin2,4
Dominique A Cadilhac1,2

1Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; 2Public Health, Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, VIC, Australia; 3Discipline of General Practice, School of Medicine, Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia; 4eastern Health Clinical School, Monash University, Clayton, VIC, Australia

Abstract: There are many recommended pharmacological and non-pharmacological therapies for the prevention of stroke, and an ongoing challenge is to improve their uptake. Personalized medicine is seen as a possible solution to this challenge. Although the use of genetic information to guide health care could be considered as the apex of personalized medicine, genetics is not yet routinely used to guide prevention of stroke. Currently personalized aspects of prevention of stroke include tailoring interventions based on global risk, the utilization of individualized management plans within a model of organized care, and patient education. In this review we discuss the progress made in these aspects of prevention of stroke and present a case study to illustrate the issues faced by health care providers and patients with stroke that could be overcome with a personalized approach to the prevention of stroke.

Keywords: stroke, prevention, personalized health care, education

Introduction

Stroke is a complex condition usually occurring in people who exhibit vascular risk factors.1 Globally, stroke is a leading cause of death and disability.2 Approximately, 16.9 million first-ever strokes and 5.9 million stroke-related deaths occur each year.3 Several effective lifestyle interventions (eg, smoking cessation) and pharmacological interventions (eg, blood pressure-lowering medication) are recommended for the prevention of stroke.4,5 However, suboptimal uptake of these interventions means there remain opportunities to improve the prevention of stroke to reduce this burden.6 Personalized medicine is a growing field in which a range of diagnostic tests, such as genetic screening and other risk stratification tools, will enable clinicians to develop evidence-based and individually tailored care plans. Additionally, personalized medicine requires consideration of patient preferences and their circumstances in clinical decision making. The objective of this review is to provide an overview of prevention of stroke and discuss how a personalized approach can improve the likely success of preventing stroke. To provide context for the issues faced in clinical practice, we first provide a case study that illustrates the difficulties encountered in the prevention of stroke.

Case study: an individualized management program for secondary stroke prevention

We conducted a qualitative analysis of the topics discussed between nurses and patients with stroke or transient ischemic attack (TIA) at education visits that were conducted...
as part of the intervention tested in the STAND FIRM (Shared Team Approach between Nurses and Doctors For Improved Risk factor Management) randomized controlled trial. The aim of the STAND FIRM trial was to improve the management of risk factors in people who returned home after being hospitalized for stroke or TIA. Briefly, the intervention included the use of a management plan that was prepared following a comprehensive risk factor assessment.

Nurses conducted education visits after the baseline assessment, and after 3-month and 12-month outcome assessments using a standard education syllabus on the prevention of stroke. The education provided was tailored to each patient and so parts of the syllabus were discussed only when relevant to the patient. Standardized literature on a range of topics was provided to patients at their request. However, the nurses often discussed topics outside the scope of the regular syllabus. The nurses also encouraged patients to discuss their main concerns of having had a stroke or TIA, and documented these concerns. The nurses also documented the advice they provided to patients to help resolve their main concerns, as well as information provided on stroke prevention using a pro forma specifically developed for these visits. An inductive approach was used to identify and summarize the major themes and subthemes derived from content analysis of these data.

Information requirements: knowledge gaps and misconceptions
Patients reported a variety of issues with the information provided to them regarding their stroke. Some patients reported to the nurses that they did not know the reason they suffered a stroke. This appeared to be a source of anxiety for these patients. Many patients also reported not understanding the reasons why their medications had been prescribed to them. In these instances, the nurses explained the causes of stroke, explained the reasons for taking the medications, and/or encouraged patients to take further interest in their medications.

Some patients were only partially aware of the reasons for being prescribed their medications and had misconceptions about the need for secondary prevention medications when risk factors were within a normally acceptable range. Other patients, who had suffered an ischemic stroke, were unhappy to be taking a cholesterol lowering medication while others questioned the need for these medications since they believed their cholesterol levels were satisfactory. For some patients, this desire to cease medication was influenced by the side effects experienced from taking the medication. For example, at the education visit that occurred 12 months after recruitment, a patient was unhappy about being prescribed a cholesterol lowering medication because he was content with his current cholesterol level and had concerns that the medication would be detrimental to his liver. Nurses clarified the rationale for taking medications and reinforced that these medications were prescribed according to guidelines and to prevent recurrent stroke.

Issues with utilization of medications
The nurses noted that some patients had poor adherence to their medications. There were also instances where the patients themselves had decided to cease medications or had declined secondary prevention medications. Sometimes patients stated that they simply forgot to take medications.

The nurses discussed ways for these patients to remember taking their medications such as developing a routine for taking medications or using a dosing aid. The nurses also encountered patients who had not taken medications because they had run out and then not renewed the script. These examples all highlighted the importance of reinforcing the reasons for taking their medications.

Financial issues were discussed in regard to medications. Some patients reported that the medications they were taking were expensive. One patient (61 years old, ischemic stroke) informed the nurse of the need to “budget for medications” for this reason. Another patient (72 years old, ischemic stroke) expressed concern that she would not be able to afford the medications when she stopped working. Regular review of medications would be ideal in order to ensure the ongoing suitability of medications from a medical and financial perspective. Regular review and reminders to renew scripts may assist as part of a personalized approach to stroke prevention.

As expected, side effects were a major reason for poor adherence or self-discontinuation of a medication. One patient (34 years old, ischemic stroke) “declined cholesterol and blood pressure medications” and was intending to “try natural therapies and relaxation” because of a desire “to avoid side effects of medications”. One patient (30 years old, ischemic stroke) admitted to taking aspirin “intermittently” as she suspected that it was causing stomach irritation. At a later education visit, this patient was still not taking aspirin regularly as she believed it was not “vital” to take this every day. This patient was informed about the importance of aspirin for secondary prevention. Another patient (82 years old, female, ischemic stroke) had been recently re-prescribed an antihypertensive medication, but had not recommenced
taking it because she did not want the return of side effects that she had previously suffered when taking this medication. Another patient (69 years old, male, ischemic stroke) had been advised to take a cholesterol lowering medication by his general practitioner (GP), but had ceased taking this medication after reading about its possible side effects. When patients reported that side effects were reasons for poor adherence, the nurses encouraged them to seek alternative medications. For example, the patient who believed aspirin to be causing gastric irritation was encouraged to discuss using enteric-coated aspirin with their GP. Some patients experienced symptoms from taking secondary prevention medications, but tolerated the symptoms and reported that they were adherent to the medications. For these patients, the nurses suggested that they speak with their GPs to receive more frequent monitoring or to find alternative secondary prevention medications.

Some patients reported that they had completely ceased taking medications due to side effects. For example, a patient (84 years old, female, ischemic stroke) had ceased taking an antihypertensive medication after developing a cough, and was concerned that this would result in increased blood pressure. The nurse advised this patient to regularly monitor her blood pressure and to discuss alternative medications with her GP.

Lessons
Our case study illustrates the many challenges faced by health care providers and patients in the prevention of stroke (Table 1). The main issues identified were: 1) knowledge gaps and misconceptions; 2) factors influencing medication adherence such as communication between health care providers and patients; and 3) the need for both reinforcement of information and review of costs of medications. Intricacies of patients necessitate a personalized approach to the prevention of stroke that incorporates targeted education, regular review and consideration of personal circumstances, including affordability of care where alternate solutions may be needed.

### Table 1

<table>
<thead>
<tr>
<th>Issues</th>
<th>Potential solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knowledge gaps and misconceptions</td>
<td>Educational interventions</td>
</tr>
<tr>
<td>Poor adherence</td>
<td>Educational interventions</td>
</tr>
<tr>
<td>• Forgetfulness</td>
<td>Regular review</td>
</tr>
<tr>
<td>• Cost of therapy</td>
<td></td>
</tr>
<tr>
<td>• Side effects</td>
<td></td>
</tr>
<tr>
<td>Communication with health care</td>
<td>Individualized management programs</td>
</tr>
<tr>
<td>providers and continuity of care</td>
<td>with regular review</td>
</tr>
</tbody>
</table>

Prevention of stroke
In the context of stroke, primary prevention refers to use of prevention strategies or therapies for people who have not yet suffered a stroke or TIA, while secondary prevention refers to similar approaches that are aimed at people who have already suffered a stroke or TIA to prevent stroke recurrence. Although the interventions used for primary prevention of stroke are similar to those for secondary prevention, there are important differences in their approach. In addition, since stroke and heart disease have similar risk factors, primary prevention strategies are often based on reducing the risk of cardiovascular disease collectively because the recommendations for treatment are often the same.

In the past, the focus of primary prevention was on the treatment of individual risk factors, with treatment initiated when a threshold for that risk factor was exceeded. However, individual risk factors are not a good measure of cardiovascular risk since most risk factors have a continuous and linear association with risk of disease events occurring, and most people have more than one risk factor. Assessment of cardiovascular risk on the basis of the combined effect of multiple risk factors (often referred to as “absolute” or “global” cardiovascular risk) is more appropriate because the cumulative effects of multiple risk factors may be additive or synergistic. Therefore, the focus of primary prevention has been shifting from the treatment of individual risk factors to the management of absolute risk. Similar to other countries, in Australia, the National Vascular Disease Prevention Alliance has endorsed algorithms and tables for risk assessment and provides a summary of the recommended assessment pathway, interventions, treatment targets, and follow-up.

Approaches to controlling risk factors for cardiovascular disease differ according to the degree of absolute risk. Lifestyle modifications are recommended for those at lower risk while more intensive treatment involving medications is recommended for those at greater risk. Importantly, a risk factor is treated, even when within a normally acceptable range, if absolute risk is high (eg, >15% chance of a stroke or heart attack within 5 years). Over time, these risk calculation tools, that combine the effects of modifiable (eg, smoking and diabetes) and non-modifiable (eg, age and sex) risk factors, have become more sophisticated. For example, the recently released “Stroke Riskometer” is available as a smart phone application and includes a risk calculation based on a broader range of risk factors than previous tools based on the Framingham equations. This may improve precision of risk, but ongoing validation work is needed.
Although positive lifestyle modifications for smoking, diet, and exercise are universally recommended, the major difference between primary and secondary stroke prevention is in regard to the provision of medications. Secondary prevention of stroke involves providing pharmacological and non-pharmacological interventions irrespective of absolute risk since patients with stroke are by definition already at “high risk”. The risk of stroke recurrence is approximately 11% at 1 year, 26% at 5 years, and 40% at 10 years post-stroke. There is also a high risk of stroke in the short-term after TIA: 9.9% at 2 days, 13.4% at 30 days, and 17.3% at 90 days. Since these risks are much greater than in the normal population, more aggressive pharmacological interventions are warranted. Importantly, secondary prevention strategies are more cost-effective than primary prevention strategies largely because of this very high risk, with the acknowledgment that they apply to fewer people.

Medications recommended in guidelines for the prevention of recurrent stroke differ according to the type of stroke that the patient has suffered and the presence of other risk factors. These recommendations, supported by meta-analyses (Table 2), are summarized below:

- **blood pressure-lowering therapy** for patients who have suffered a stroke or TIA. 
- **Cholesterol lowering therapy** for patients who have suffered an ischemic stroke or TIA.
- **Antiplatelet therapy** for patients without atrial fibrillation who have suffered an ischemic stroke or TIA.
- **Anticoagulant therapy** for patients with atrial fibrillation who have suffered an ischemic stroke or TIA.
- **New oral anticoagulants (NOACs)** may be used as an alternative to warfarin. Compared to warfarin all NOACs had a reduced risk of hemorrhagic stroke, and were either superior or non-inferior in terms of major bleeding risk, except for gastrointestinal bleeding. There are also practical advantages for the use of NOACs over warfarin: they are simpler to monitor because they have fixed doses and do not require monitoring of anticoagulant effects; have a short half-life; and have few drug and food interactions. The major disadvantages of NOACs include a short half-life which makes NOACs ineffective for patients with poor compliance, the absence of a blood test to determine the strength of the anticoagulant effect, no antidote for reversal of the anticoagulant effect, concerns about safety of thrombolysis while on NOACs, and the need to monitor renal function because of increases in plasma concentrations of NOACs in people with poor renal function. NOACs are also more expensive than warfarin, but have been shown to be cost-effective for the secondary prevention of stroke. In Australia, these medications have been subsidized by the government under the Pharmaceutical Benefits Scheme (www.pbs.gov.au/).

The cumulative risk reductions from using a combination of these medications for secondary prevention may be substantial. Although there is limited direct evidence of the combined benefit of these medications for patients who have suffered a stroke or TIA, in simulation modeling of patients with heart attack, an estimated 75% relative risk reduction in stroke, heart attack, and death could be achieved with lifestyle modification and a combination of secondary prevention medications. Similar benefits could be elicited for patients with stroke since stroke and heart attack have a similar pathophysiology and recommended treatment. The use of combination therapy may also be favorable because it produces greater and timelier effects at lower doses of medications, minimizes side effects, and improves adherence by simplifying the medication regimen.

---

**Table 2** Summary of meta analyses of antihypertensive, antiplatelet, anticoagulant, and cholesterol lowering drugs used for secondary prevention in patients with stroke and TIA

<table>
<thead>
<tr>
<th>Study, year</th>
<th>Type of patients</th>
<th>Primary outcome</th>
<th>Treatment</th>
<th>Control</th>
<th>RRR with treatment % (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lakhani and Sapko, 2009</td>
<td>Stroke, TIA</td>
<td>Stroke, MI, VD</td>
<td>Blood pressure-lowering</td>
<td>Placebo</td>
<td>31 (14–43)</td>
</tr>
<tr>
<td>Manktelow and Potter, 2009</td>
<td>Stroke, TIA</td>
<td>Stroke</td>
<td>Statin</td>
<td>Placebo</td>
<td>12 (0–23)</td>
</tr>
<tr>
<td>Algra and van Gijn, 1999</td>
<td>Non-disabling stroke, TIA</td>
<td>Stroke, MI, VD</td>
<td>Aspirin</td>
<td>Placebo</td>
<td>13 (6–19)</td>
</tr>
<tr>
<td>Saxena and Koudstaal, 2004</td>
<td>NRAF and minor ischemic stroke or TIA</td>
<td>Stroke, MI, VD</td>
<td>Warfarin</td>
<td>Aspirin</td>
<td>33 (9–50)</td>
</tr>
<tr>
<td>Ntaios et al, 2012</td>
<td>NRAF and stroke or TIA</td>
<td>Stroke, systemic embolism Major bleeding</td>
<td>NOACs</td>
<td>Warfarin</td>
<td>15 (1–26)</td>
</tr>
</tbody>
</table>

**Abbreviations:** TIA, transient ischemic attack; MI, myocardial infarction; VD, vascular death; NRAF, non-rheumatic atrial fibrillation; MR-DP, modified-release dipyridamole; RRR, relative risk reduction; CI, confidence interval; NOACs, new oral anticoagulants.
**Poor adherence and treatment gaps**

Adherence to a medication regimen is generally defined as the extent to which patients take medications as prescribed by their health care providers. The level of adherence that is deemed as acceptable varies from study to study, but better adherence to therapy is associated with better outcomes. In an Italian study, 51% of patients newly treated for hypertension were adherent to their medication. There is also some evidence that even patients with stroke have poor adherence to medications used for stroke prevention. In a study conducted in Canada, Khan et al assessed adherence to antihypertensive medications at 1 year after stroke. Depending on the type of antihypertensive medication prescribed, 62%–76% of patients were taking their medication on ≥80% of days.

There is evidence that the utilization of therapies for the prevention of stroke can be improved. In a study conducted in the Netherlands, de Koning et al investigated the quality of care in general practice provided to patients prior to their hospitalization for stroke. The management of hypertension, diabetes mellitus, TIA, peripheral vascular disease, cardiac failure, and angina pectoris prior to stroke was assessed by a panel of GPs. These GPs adjudicated that one-third of the patients received suboptimal care that possibly or likely failed to prevent stroke. There is also evidence that patients who have had a stroke are receiving suboptimal care.

**Definition of personalized medicine**

Personalized medicine may solve the problems of managing risk factors and preventing stroke. There is no universally accepted definition of personalized medicine. Some definitions incorporate the use of genetic information to individualize the provision of care. A definition recommended by Schleidgen et al following a systematic review, is that:

> personalized medicine seeks to improve stratification and timing of health care by utilizing biological information and biomarkers on the level of molecular disease pathways, genetics, proteomics as well as metabolomics.

Similar terms to personalized medicine include “precision medicine” and to a lesser extent “patient-centered care”. To date, routine genetic testing has not been adopted into strategies for preventing stroke because the genes associated with stroke that have been identified do not adequately predict overall stroke risk. However, genetic information has applications in determining the effectiveness of medications for an individual. For example, genetic testing can be used to improve the delivery of anticoagulant therapy. The major limitation of the definition proposed by Schleidgen et al is that it does not incorporate individualized aspects of a patient-centered approach to health care. Patient-centered health care emphasizes consideration of patients’ preferences and values, provision of emotional and physical support, education, coordination of care, and involvement of family and friends. This can be facilitated with discussion between health care providers and patients, and shared decision-making. The tools used to assist clinical decision-making usually incorporate routinely collected individual clinical information that assist clinicians to deliver appropriate health care for a particular patient. Clearly, health care can be individualized regardless of whether or not genetic information is available to assist clinical decision-making. Therefore, we have adopted a broader view of personalized medicine that combines the definition proposed by Schleidgen et al and aspects of patient-centered health care.

**Tools to support clinical decision-making**

To facilitate personalized medicine, time-poor clinicians require effective tools to support their clinical decision-making. In future, there is likely to be a greater reliance on software to assist clinical decision-making as this is expected to improve the quality of care provided. Individual clinical information can be used within the software to support a decision to treat. Evidence for the use of clinical decision-support software for the prevention of stroke is limited, but some benefit for its use for the management of risk factors for stroke has been demonstrated.

There are increasingly effective risk stratification tools that assist with clinical decision-making, particularly in the primary prevention setting. In general, risk stratification tools have become more personalized with their increasing complexity. There is some qualitative evidence that the absolute cardiovascular risk approach to conveying risk is considered by patients to be personalized, but this method of conveying risk is underutilized by clinicians. The development of the Stroke Riskometer and other similar smart phone applications may facilitate better utilization of an absolute risk approach to prevention management in future. Risk stratification is particularly important in the decision to prescribe an anticoagulant medication to patients with atrial fibrillation. Although there is evidence from randomized controlled trials of an overall benefit for patients with atrial fibrillation prescribed anticoagulant medications, patients taking these medications are at an increased risk of intracerebral hemorrhage. In addition, stroke in patients with atrial fibrillation is not always embolic. Therefore, the risks
and benefits of anticoagulant therapy need to be carefully considered. Use of the CHA2DS2-VASc45 and HAS-BLED45 risk stratification tools are recommended to help weigh up the risks of ischemic stroke and intracerebral hemorrhage in patients with atrial fibrillation and therefore assist with the decision to prescribe anticoagulant medications. The type of anticoagulant medication (eg, warfarin or NOACs) prescribed should take into account the personal circumstances of the patient and determine the best fit for ensuring adherence and maintaining quality of life, since there are advantages and disadvantages of each medication.

**Individualized management programs**

As described earlier, in the long term after stroke many patients are not prescribed medications that may help to prevent recurrent stroke46 and often they have poorly controlled risk factors5-7 and unmet needs.8 An individualized care plan, which is developed with the patient while in hospital, may improve continuity of care once the patient returns to the community. In Australia, it is recommended that patients discuss their individualized care plan with their GP once they are discharged from hospital.9 GPs and patients are encouraged to review these plans periodically. The plan typically includes information on risk factors, therapy and equipment required, and contact details of community support services. In Australia, there is an existing framework for the use of these plans that is Medicare-funded in order to provide additional incentive for GPs to use them.50

Individualized secondary prevention programs for patients with heart disease have been shown to reduce mortality by up to 25%, reduce recurrent cardiovascular events by up to 24%, improve prescription of medications, improve quality of life, and improve the management of several risk factors.51,52 Several of these studies have involved individualized risk factor assessment and management provided through general practices (Table 3).52 Trials of programs for the secondary prevention of stroke have been tested in only a few clinical trials that have involved relatively small numbers of patients with stroke.53 These studies have been heterogeneous and have primarily demonstrated benefits for lowering blood pressure and promoting lifestyle change, but not for reducing the risk of cardiovascular disease (Table 4). However, economic modeling provides evidence for cost-effectiveness of individualized care for the management of blood pressure and lifestyle risk factors in patients who have suffered a stroke, with a median cost per quality adjusted life year gained estimated at less than AU$5,000 (reference year 2004).14

Nurse-led care offers a complementary alternative to prevention management directed by GPs. This form of care has been shown to be effective for reducing blood pressure in patients with hypertension;14 improving glycemic control and reducing mortality in patients with diabetes;55 and for reaching target cholesterol levels.56 Nurse-led care can also have effects on preventing cardiovascular events in people at risk of stroke. In a study by Hendriks et al.,57 712 patients

<table>
<thead>
<tr>
<th>Study, year</th>
<th>n</th>
<th>Follow-up</th>
<th>Primary outcome measure</th>
<th>Significant primary outcome results</th>
</tr>
</thead>
</table>
| Murchie et al, 200348 | 1,343 | 5 years   | – Improvements in prescription of secondary prevention therapies  
– Total mortality  
– Coronary events | – Improved pharmacological and lifestyle management  
– Decreased risk of mortality  
– Decreased risk of coronary events  
– Nil |
| Munoz et al, 200759 | 983   | 3 years   | – Readmission for unstable angina, AMI, heart failure, arrhythmias, stroke, or coronary artery revascularization |  
– Prescription of β-blocker for patients with AMI  
– Total cholesterol <5 mmol/L for patients with CHD  
– Prescription of ACEI for patients with LVSD |  
– More patients with AMI prescribed β-blocker  
– More patients with CHD cholesterol <5 mmol/L  
– Reduced blood pressure  
– Reduced low-density lipoprotein levels  
– Increased prescriptions to statins  
– Decreased hospitalization |
| Khunti et al, 200760,61 | 1,316 | 1 year    | – Prescription of β-blocker for patients with AMI  
– Total cholesterol <5 mmol/L for patients with CHD  
– Prescription of ACEI for patients with LVSD |  
– More patients with AMI prescribed β-blocker  
– More patients with CHD cholesterol <5 mmol/L  
– Reduced blood pressure  
– Reduced low-density lipoprotein levels  
– Increased prescriptions to statins  
– Decreased hospitalization |
| Wood et al, 200862 | 1,940 | 1 year    | – Blood pressure  
– Blood lipids and glucose  
– Prescription of secondary prevention medications |  
– Target levels for blood pressure and cholesterol  
– Hospital admission  
– Changes in physical and mental health status |

**Table 3** Randomized controlled trials of programs for risk management of patients with coronary heart disease involving general practitioners

*Note:* Patients with coronary heart disease and chronic heart failure.

**Abbreviations:** AMI, acute myocardial infarction; CHD, coronary heart disease; LVSD, left ventricular systolic dysfunction; ACEI, ACE inhibitor.
with AF were randomized to nurse-led or usual care. Nurses used guideline-based decision-support software to recommend therapy. Symptoms, type of AF, and the risk of stroke were considered when making the recommendations. These recommendations were approved by a cardiologist. Patients in the nurse-led care group had a 72% reduction in the risk of cardiovascular death and a 34% reduction in the risk of cardiovascular hospitalizations when compared to patients provided with usual care.

**Education to improve adherence to therapies**

Many factors have been found to affect adherence to therapy, including health system, patient, and clinician factors. For example, non-adherence due to cost of medications may be affected by all three factors: high medication costs which may discourage utilization; patients may not purchase recommended medications because the cost of the medication outweighs their perceived benefit; and clinicians may prescribe a medication that is inappropriate for a patient’s financial situation. In addition, caregivers play an important role in patients’ care and the education of caregivers can improve adherence to therapies prescribed to the patient.

Personalized approaches to education may be preferred in order to improve adherence to prescribed therapies and uptake of positive lifestyle modifications. Improving patient knowledge about stroke and the benefits of secondary prevention medications is important because attitudes to medications affect their utilization. Patients who believed the benefits of their medication to be low were found to be less likely to be adherent when compared to patients who believed that the benefits of their medications were outweighed by the negatives. Similarly, in a study of patients who had suffered a stroke, those who reported poor adherence to medications more often believed that their medications were not useful. Ongoing utilization of secondary prevention medications is associated with a better understanding of reasons for taking medications.

Educating patients about the medications and lifestyle changes that reduce the risk of stroke recurrence are likely to improve adherence to recommended therapies. There is some evidence that providing detailed information about medications improves adherence. The effect of these educational interventions on clinical outcomes such as recurrent stroke and mortality is unknown. However, such interventions should be considered as better adherence to medications is associated with better outcomes. Education has also been shown to be effective for improving clinical outcomes in patients with heart disease, and so may be similarly effective for patients who have suffered a stroke. In patients with heart disease, secondary prevention programs with risk factor education and counseling reduced all-cause mortality by 13%, and improved risk factor profiles and utilization of prevention medications.

The method of educating patients is important when encouraging better adherence to recommended lifestyle changes. Advice to change behaviors for stroke prevention is most effective at changing health behaviors when using a motivational interviewing framework. Motivational interviewing is a counseling method used to encourage behavior...
change by building motivation to change in a way that is directive and patient-centered. The four guiding principles of motivational interviewing are: 1) resisting the righting reflex and exploring motivations for change; 2) understanding patients' motivations; 3) listening with empathy; 4) empowering your patient. Motivational interviewing is effective for reducing alcohol consumption, weight, serum cholesterol levels, and systolic blood pressure, increasing smoking cessation, and improving adherence to antihypertensive medications. There may be merits in using social media and digital platforms to deliver personalized patient education in future, but this requires further research to determine its effectiveness in encouraging behavior change.

Limitations of a personalized approach

Personalized health care may require considerable time investment from healthcare providers and patients, particularly the educational interventions for encouraging lifestyle behavior change. Multiple education sessions are recommended in order to have patients consider changes, prepare for change, and maintain change. In addition, clinicians require training in effective educational techniques such as motivational interviewing.

A personalized approach to health care may be limited depending on the patient's level of autonomy. For example, patients who are cognitively impaired may not be able to express their preferences and values, and therefore would be unable to actively participate in the decision-making process about their treatment. Healthcare providers would require greater input from the patient's family or carer in these instances.

There may be challenges to providing personalized care for people with concurrent illnesses. There may be difficulties coordinating care when consultations with multiple healthcare providers are required and conflicting recommendations from different providers may need resolution. Generally, patients with several concurrent illnesses require a greater number of medications. Promoting adherence to therapies can be challenging in these circumstances. Funding policies for chronic disease management that support more streamlined care between multiple clinicians and permit greater time for education are required. In Australia, GPs are reimbursed for providing or coordinating such activities through Medicare, the national public health care scheme.

Conclusion

Improvements in the prevention of stroke can be achieved with greater personalization of care. Firstly, appropriate selection of patients eligible for therapies is required and should be based on their risk profile. Selection of eligible patients has become more personalized with the development of more complex risk stratification tools. Secondly, in those found to be eligible for therapies used for the prevention of stroke, personalized care should be provided. Patients' preferences and values should be considered in a coordinated model of care. Additionally, provision of emotional and physical support, education and involvement of family and friends is recommended.

Existing treatment protocols recommended in guidelines may change as risk stratification tools are constantly refined. Further work is required to develop effective care planning and education interventions for the prevention of stroke. Tools to facilitate shared decision-making for time-poor clinicians and appropriate funding policies to support these activities are needed, including those that maximize the potential for interdisciplinary care and communication. Overall, personalized medicine in the context of stroke assists delivery of therapy and may improve adherence to prescribed therapies, which in turn should improve outcomes for patients.

Acknowledgments

The STAND FIRM trial was funded by the NHMRC (586605). Thanks to Sue Mosley and Mary Staio who undertook the education visits for the STAND FIRM trial.

Disclosure

DAC has an unrestricted educational grant from Boehringer Ingelheim for the Victorian Stroke Telemedicine Project and the Australian Stroke Clinical Registry. AGT has served on advisory boards for Sanofi-Aventis, Novartis, Schering-Plough, Solvay Pharmaceuticals, and AMGEN. He has also prepared educational material for Servier Laboratories, AstraZeneca, Bristol-Myers Squibb, and MediMark and received conference and travel support from Bayer HealthCare AG, Merck Sharp and Dohme, Novartis, and Sanofi-Aventis. CFB has an unrestricted educational grant from Boehringer Ingelheim for the Victorian Stroke Telemedicine Project. The authors have no other conflicts of interest to disclose.
References


